Drugs / Nanocrystalline silver
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00076375 | Nov 2003 → Apr 2004 | atopic eczema | Nucryst Pharmaceuticals | Completed | No outcome recorded |
| Phase 41 trial · 1 missed | ||||||
| Phase 4 | NCT02108535 | Nov 2013 → Aug 2014 | — | University of Sorocaba | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nanocrystalline silver | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00076375 ↗ |
| Known as | NPI | “Nanocrystalline silver cream (NPI)” NCT00076375 ↗ |
| Route | Topical | “Two Concentrations of Nanocrystalline Silver Cream (NPI) Applied Twice Daily” NCT00076375 ↗ |